Johnson & Johnson beats Q2 2026 Wall Street estimates and raises full-year guidance as sales top $25B, driven by oncology and MedTech.

Earnings report for JNJ expected on July 15, with analysts predicting $2.85/share & $25.06B revenue. Stock price target raised to $287/share.

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook